Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment.

Trial Profile

Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2010

At a glance

  • Drugs Linagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 22 Sep 2010 New trial record
    • 20 Sep 2010 Results reported at the 46th annual meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top